Overall K-M Mortality (a), day 14 (b) and day 28 (c).
obesity, death, respiratory failure, CVD, CPD, diabetes
OBESITY, CVD, RESPIRATORY FAILURE, REGRESSIONS, DIABETES
A total of 11 (11.2%) patients experienced respiratory failure, defined as those requiring high-flow oxygen therapy, noninvasive ventilation, invasive ventilation, and/or death (levels 5–8 on COVID ordinal scale). Most of the patients who experienced respiratory failure were in the control group (Aggrenox: 4 vs control: 7), but these data failed to reach statistical significance on univariate analyses (p = 0.34). When controlling for possible risk factors including age, sex, obesity status, and comorbidities (CVD, CPD, diabetes, smoking status), multivariate analyses demonstrated non-significant differences between Aggrenox and the control group on the outcome of respiratory failure through day 14 (OR [95% CI]: 0.49 [0.07, 3.51], p = 0.48) and through day 28 (OR [95% CI]: 0.21 [0.02, 2.57], p = 0.22). Multivariate regressions for mortality and respiratory failure are shown in S3 Table in 